Veronique Anne Dartois

This study identifies SPHK2 as a therapeutic target in G3MB, showing that its inhibition restores anti-tumor immunity and improves survival in mouse models, with enhanced effects when combined with radiation.

The paper shows in vitro models of tuberculosis lesions predict treatment responses in marmosets better than conventional methods.

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

Rabbit lesion microdissection and pharmacokinetic modeling show bedaquiline takes months to reach deep caseum and years to clear, while TBAJ-587 and TBAJ-876 shorten these windows.

This study identifies a candidate transmission survival genome of Mycobacterium tuberculosis by exposing it to model aerosol fluid and analyzing gene contributions to survival during transmission.

This study identifies in vivo chemical-genetic interactions in tuberculosis that reveal novel drug targets and mechanisms, showing differences from in vitro results and highlighting metabolic dependencies affecting drug efficacy.

This paper develops an engineered Mycobacterium tuberculosis strain with kill switches for a safe TB human challenge model, showing rapid clearance and low escape rates.

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.

This paper introduces a multimodal imaging workflow combining MALDI-MSI and IF microscopy to enhance spatial single-cell metabolomics, validated on mouse spleen sections.